© 2006 European Society for Medical Oncology
symposium article |
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models
1 Department of Experimental Medicine and Pathology, University La Sapienza, 00161 Rome; 2 Department of Experimental Medicine, University of L'Aquila, 67010 L'Aquila; 3 Medical Oncology, IDI-IRCCS, 00167, Rome; 4 U. O. Oncologia Medica e Terapie Integrate, A.O. Universitaria Policlinico G. Martino, 68123 Messina; 5 Department of Oncology, Catholic University of the Sacred Heart, Campobasso; 6 Department of Medical Oncology, Regina Elena Cancer Institute, Rome; 7 Neuromed Institute, Pozzilli, Italy
* Correspondence to: Dr G. Giannini, Department of Experimental Medicine and Pathology, University La Sapienza, Policlinico Umberto I, Viale Regina Elena, 324 00161, Rome, Italy. Tel: +39-06-4958637; Fax: +39-06-4461974; E-mail: giuseppe.giannini{at}uniroma1.it
Background: Breast cancer is an extremely complex disease, characterized by a progressive multistep process caused by interactions of both genetic and non-genetic factors. A combination of BRCA1 and BRCA2 gene mutations appears responsible for about 20%–30% of the cases with breast cancer familial history. The prevalence of BRCA1/2 pathogenic mutations largely varies within different populations; in particular, the rate of mutations in Italian breast and/or ovarian cancer families is rather controversial and ranges from 8% to 37%.
Patients and methods: Of the 152 breast/ovarian cancer families counseled in our centre, 99 were selected for BRCA1/2 mutation screening according to our minimal criteria. The entire coding sequences and each intron/exon boundary of BRCA1/2 genes were screened by direct sequencing (PTT limited to BRCA1 exon 11). For each proband, the a priori probability of carrying a pathogenic BRCA1/2 germline mutation was calculated by means of different mutation prediction models (BRCApro, IC and Myriad Table) in order to evaluate their performances.
Results: Our analysis resulted in the identification of 25 and 52 variants in the BRCA1 and BRCA2 genes, respectively. Seventeen of them represent novel variants, including four deleterious truncating mutations in the BRCA2 gene (472insA, E33X, C1630X and IVS6+1G>C). Twenty-seven of the 99 probands harbored BRCA1 (n = 15) and BRCA2 (n = 12) pathogenic germline mutations, indicating an overall detection rate of 27.3% and increasing by more than 15% the spectrum of mutations in the Italian population. Furthermore, we found the lowest detection rate (19.4%) in pure hereditary breast cancer family subset. All of the prediction models showed praises and faults, with the IC software being extremely sensitive but poorly specific, compared to BRCApro. In particular all models accumulated most false-negative prediction in the HBC subset. Interestingly preliminary results of a study addressing the presence of genomic rearrangements in HBC probands with BRCApro or IC prediction scores 
95%, provided evidence for additional mutations undetectable with our conventional screening for point mutations.
Conclusions: Altogether our results suggest that HBC families, the largest pool in our series, represent an heterogeneous group where the apparently faulty performances of the prediction models might be at least partially explained by the presence of additional kinds of BRCA1/2 alteration (such as genomic rearrangements) or by mutations on different breast cancer related genes.
Key words: BRCA1, BRCA2, breast cancer, familial cancer, ovarian cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S G Hadfield, S Horara, B J Starr, S Yazdgerdi, D Marks, D Bhatnagar, R Cramb, S Egan, R Everdell, G Ferns, et al. Family tracing to identify patients with Familial Hypercholesterolaemia: the second Audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project Ann Clin Biochem, January 1, 2009; 46(1): 24 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Giannini, C. Capalbo, L. Ottini, A. Buffone, L. De Marchis, E. Margaria, D. Vitolo, E. Ricevuto, C. Rinaldi, M. Zani, et al. Clinical Classification of BRCA1 DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain J. Clin. Oncol., September 1, 2008; 26(25): 4212 - 4214. [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Palma, S. M. Domchek, J. Stopfer, J. Erlichman, J. D. Siegfried, J. Tigges-Cardwell, B. A. Mason, T. R. Rebbeck, and K. L. Nathanson The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families Cancer Res., September 1, 2008; 68(17): 7006 - 7014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Capalbo, A. Buffone, A. Vestri, E. Ricevuto, C. Rinaldi, M. Zani, S. Ferraro, L. Frati, I. Screpanti, A. Gulino, et al. Does the Search for Large Genomic Rearrangements Impact BRCAPRO Carrier Prediction? J. Clin. Oncol., June 20, 2007; 25(18): 2632 - 2634. [Full Text] [PDF]
|
|